This week, the pharmaceutical industry consolidated further after Bristol-Myers Squibb (BMY: Charts, News) announced a $5.3 billion deal to acquire diabetes drug manufacturer Amylin Pharmaceuticals AMLN (AMLN: Charts, News). New York-based Bristol acquired San Diego, California-based Amylin for $31 per share, a 10% premium to its June 29 closing price. Bristol had made a previous attempt to acquire Amylin in February for $22 per share. Stock Analysis Rival drugmaker AstraZeneca (AZN: Charts, News) also announced that it will pay Bristol $3.4 billion to help develop Amylinâ s drug pipeline. In exchange, AstraZeneca will reap the benefits and share the risks of the joint venture. Bristol reportedly outbid AztraZeneca, Sanofi (SAN: Charts, News) and Merck (MRK: Charts, News) to gain control of Amylin. From the deal, Bristol gains Amylinâ s two U.S. approved diabetes drugs – a twice-daily injection medication called Byetta, and a longer-acting, once-a-week medication named Bydureon. Byetta notably generated $518 million in sales last year, while Bydureon, still new to the market, has been forecast to become a $2 billion product in the coming year. The acquisition of Amylin fills a noticeable void in Bristolâ s drug portfolio. This January, Bristolâ s own diabetes product, dapagliflozin, was rejected by the Food and Drug Administration. Diabetes has become a top priority for the major pharmaceutical players. With 346 million global patients, the World Health Organization estimates fatalities may double within the next two decades, making effective diabetes medication a high priority. Analysts believe that Bristol needs a new source of strong revenue after its top product of 2011, the blood-thinner Plavix, came under heavy generic competition in May. Plavix accounted for $7.1 billion of Bristolâ s annual sales last year. To shield itself from the threat of patent expirations – which wiped out an estimated $34 billion in annual sales across the pharmaceutical industry – Bristol has been on an acquisition spree this year, concluding five acquisitions worth over $1 billion each so far. In the previous two years, Bristol had only acquired three companies exceeding the billion dollar mark. Analysts believe that the losses across the industry due to the loss of patent protection will rise to $147 billion by 2015, which explains Bristolâ s urgency in acquiring new patents through costly takeovers. Seamus Fernandez, an analyst at Leerink Swann & Co., believes that this is only the beginning of industry consolidation. â
Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $5.3 BillionBy: Leo Sun, dated July 3rd, 2012
Recent Commentary and Articles
- August Named the Best Month for Stocks Since February
- Will September’s Volatile Reputation Live On?
- Splunk (SPLK) Shares Up on Better than Expected Earnings
- Apple Finalizes Sept. 9th Event; JPMorgan Victim of Very Sophisticated Cyberattack
- Could a Guess Buyout Happen?
- Tiffany Gets Returned, but Bigger Returns Could Be Ahead
- Tekmira Pharmaceuticals (TKMR) Stock Up on Rumored Takeover